The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis’s oncology capabilities.

ZURICH, July 6 (Reuters) - Swiss drugmaker Novartis said on Monday it had agreed to pay up to $1.5 billion for U.K.-based ...

Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to ...

This oncology biotech advancing targeted therapies reported a notable insider sale amid ongoing clinical-stage development.

Novartis AG is to pay $1.1 billion up front to acquire Myricx Bio Ltd., a preclinical-stage antibody-drug conjugate (ADC) ...

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the ...

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota ...